InsiderSignalSign in

← Insider buys

VNDA

Vanda Pharmaceuticals Inc. · Healthcare

Insiders sold $2.6M of Vanda Pharmaceuticals Inc. in the last 12 months and bought none

$0Bought, 12 mo

$2.6MSold, 12 mo

$276.3MMarket cap

VNDA over the last year

No insider buys filed in this year

VNDA after insider buys

3 months after each buy, from the first price a copier could get.

−4.5%Average

−8.1 ptsVs S&P 500

3 of 10Higher

10 buys since 2025 with 3 months of prices.

Every filing

104 insider filings since 2016, newest first

Timothy Williams · SVP and General Counsel

$351K−10.0%Mar 4

Kevin Patrick Moran · SVP, CFO and Treasurer

$351K−9.0%Mar 4

Joakim Wijkstrom · SVP and CMO

$255K−8.0%Mar 4

Mihael Hristos Polymeropoulos · President and CEO

$1.3M−5.0%Mar 4

Gunther Birznieks · SVP, Business Development

$351K−8.0%Mar 4

Mihael Hristos Polymeropoulos · President and CEO

Mihael Hristos Polymeropoulos · President and CEO

Mihael Hristos Polymeropoulos · President and CEO

$84K+1.0%May 19

Mihael Hristos Polymeropoulos · President and CEO

Mihael Hristos Polymeropoulos · President and CEO

Mihael Hristos Polymeropoulos · President and CEO

Mihael Hristos Polymeropoulos · President and CEO

Mihael Hristos Polymeropoulos · President and CEO

Mihael Hristos Polymeropoulos · President and CEO

Mihael Hristos Polymeropoulos · President and CEO

Stephen Ray Mitchell · Director

$26K−10.0%Nov 18

Timothy Williams · SVP and General Counsel

$73K−8.0%Mar 6

Joakim Wijkstrom · SVP and CMO

$72K−11.0%Mar 6

Mihael Hristos Polymeropoulos · President and CEO

$231K−3.0%Mar 6

Kevin Patrick Moran · SVP, CFO and Treasurer

$63K−6.0%Mar 6

Gunther Birznieks · SVP, Business Development

$73K−5.0%Mar 6

Stephen Ray Mitchell · Director

$39K−18.0%Aug 11

Kevin Patrick Moran · SVP, CFO and Treasurer

$101K−11.0%Jun 20

Timothy Williams · SVP and General Counsel

$96K−14.0%Jun 15

Timothy Williams · SVP and General Counsel

$105K−14.0%Mar 6

Joakim Wijkstrom · SVP and CMO

$74K−9.0%Mar 6

Mihael Hristos Polymeropoulos · President and CEO

$281K−3.0%Mar 6

Kevin Patrick Moran · SVP, CFO and Treasurer

$87K−9.0%Mar 6

Gunther Birznieks · SVP, Business Development

$105K−8.0%Mar 6

Timothy Williams · SVP and General Counsel

$56K−8.0%Dec 16

Mihael Hristos Polymeropoulos · President and CEO

$1.0M−6.0%Dec 7

Kevin Patrick Moran · SVP, CFO and Treasurer

$51K−4.0%Dec 7

Joakim Wijkstrom · SVP and CMO

$37K−4.0%Aug 23

Timothy Williams · SVP and General Counsel

$86K−8.0%Aug 17

Stephen Ray Mitchell · Director

$26K−29.0%Jun 14

Thomas Watkins · Director

$64K−9.0%Jun 3

Richard W Dugan · Director

$64K−9.0%Jun 2

Timothy Williams · SVP and General Counsel

$134K−10.0%Mar 2

Joakim Wijkstrom · SVP and CMO

$78K−7.0%Mar 2

Mihael Hristos Polymeropoulos · President and CEO

$414K−3.0%Mar 2

Kevin Patrick Moran · SVP, CFO and Treasurer

$139K−9.0%Mar 2

Gunther Birznieks · SVP, Business Development

$175K−8.0%Mar 2

Mihael Hristos Polymeropoulos · President and CEO

$1.6M−7.0%Dec 2

Aranthan Jones II · Chief Corp. Affairs Officer

$277K−17.0%Sep 17

Stephen Ray Mitchell · Director

$320K−67.0%Sep 13

Joakim Wijkstrom · SVP and CMO

$56K−5.0%Aug 23

Timothy Williams · SVP and General Counsel

$60K−4.0%Aug 17

Kevin Patrick Moran · SVP, CFO and Treasurer

$41K−2.0%Jul 30

Aranthan Jones II · Chief Corp. Affairs Officer

$143K−8.0%Jul 27

Stephen Ray Mitchell · Director

$97K−35.0%Jun 17

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.